Search research articles
Contact Us
Filters
Showing results (1-10 of 97) with videos related to
Page
of 10
Sort By:
Clinical and Translational Science
|
September 24, 2020
Enabling Warp Speed Using the Hypervelocity Innovation Model: A Blue Print for Drug Development in Pandemics
Rajesh Krishna
Journal of Clinical Pharmacology
|
April 3, 2026
Beyond Impossibility: Reimagining Clinical Evidence for Children with Ultra-Rare Diseases
Rajesh Krishna
Journal of Clinical Pharmacology
|
September 1, 2009
Model-based evaluation of QTc interval risk: an increasing emphasis on early decision making
Rajesh Krishna
Journal of Pharmacokinetics and Pharmacodynamics
|
April 27, 2023
Special issue: Model-informed drug development in rare diseases: connecting the dots in an information rich ecosystem
Rajesh Krishna
Journal of Clinical Pharmacology
|
November 11, 2025
US FDA's Strategic Transition of Animal to Non-Animal Alternatives for Monoclonal Antibody Development: A Much Needed Fuel to Incentivize Innovation
Rajesh Krishna
Drug Discovery Today
|
April 12, 2026
Strategic adoption of model-informed drug development (MIDD) as an overarching business model in biotechnology and life science industry
Rajesh Krishna
Journal of Clinical Pharmacology
|
May 11, 2020
The Clinical Pharmacology Sections in Drug Package Inserts: Do We Need to Reexamine the Basis?
Rajesh Krishna
Journal of Clinical Pharmacology
|
May 19, 2021
Is QTc the Right Surrogate in Adequately Assessing the Risk for TdP for Development Compound Candidates? A Call to Investigate
Rajesh Krishna
Journal of Clinical Pharmacology
|
August 22, 2006
Quantitative clinical pharmacology: Making paradigm shifts a reality
Rajesh Krishna
Journal of Clinical Pharmacology
|
November 27, 2025
Has Pharmacologic Contextualization Become a Lost Art? How Can We Revive the Integrator Pharmacologist?
Rajesh Krishna
Page
of 10
Search research articles
Search
Showing results (1-10 of 97) with videos related to
Sort By:
Page
of 10
Clinical and Translational Science
|
September 24, 2020
Enabling Warp Speed Using the Hypervelocity Innovation Model: A Blue Print for Drug Development in Pandemics
Rajesh Krishna
Journal of Clinical Pharmacology
|
April 3, 2026
Beyond Impossibility: Reimagining Clinical Evidence for Children with Ultra-Rare Diseases
Rajesh Krishna
Journal of Clinical Pharmacology
|
September 1, 2009
Model-based evaluation of QTc interval risk: an increasing emphasis on early decision making
Rajesh Krishna
Journal of Pharmacokinetics and Pharmacodynamics
|
April 27, 2023
Special issue: Model-informed drug development in rare diseases: connecting the dots in an information rich ecosystem
Rajesh Krishna
Journal of Clinical Pharmacology
|
November 11, 2025
US FDA's Strategic Transition of Animal to Non-Animal Alternatives for Monoclonal Antibody Development: A Much Needed Fuel to Incentivize Innovation
Rajesh Krishna
Drug Discovery Today
|
April 12, 2026
Strategic adoption of model-informed drug development (MIDD) as an overarching business model in biotechnology and life science industry
Rajesh Krishna
Journal of Clinical Pharmacology
|
May 11, 2020
The Clinical Pharmacology Sections in Drug Package Inserts: Do We Need to Reexamine the Basis?
Rajesh Krishna
Journal of Clinical Pharmacology
|
May 19, 2021
Is QTc the Right Surrogate in Adequately Assessing the Risk for TdP for Development Compound Candidates? A Call to Investigate
Rajesh Krishna
Journal of Clinical Pharmacology
|
August 22, 2006
Quantitative clinical pharmacology: Making paradigm shifts a reality
Rajesh Krishna
Journal of Clinical Pharmacology
|
November 27, 2025
Has Pharmacologic Contextualization Become a Lost Art? How Can We Revive the Integrator Pharmacologist?
Rajesh Krishna
Page
of 10